A New Minimal-invasive Brain Tissue Probe Applying Near Infrared Spectroscopy

NeMoDevices AG3 enrolled

Overview

To assess the feasibility of a new brain tissue probe for multi-parameter neuromonitoring (NeMo Probe) and the accuracy of measurement values. To demonstrate the ability of the NeMo probe to detect changes in cerebral hemodynamics and oxygenation during cerebrovascular events monitored with established methods including brain tissue oxygenation tension and microdialysis

Study Type

INTERVENTIONAL

Allocation

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

Conditions

Spontaneous Subarachnoid Hemorrhage

Interventions

NeMo ProbeDEVICE

A new minimal-invasive brain tissue probe applying near infrared spectroscopy

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Males and females aged 18-75 years (inclusive) * Patients with high-grade subarachnoid hemorrhage (WFNS 4-5) * Decreased level of consciousness with the need for intracranial pressure monitoring * Successful exclusion of the ruptured aneurysm with clipping or coiling * Women of childbearing potential must have a negative serum pregnancy test * Written informed consent obtained by a legal representative Exclusion Criteria: * Significant kidney and/or liver disease * Any severe unstable concomitant condition or disease (e.g. cancer, coronary disease) or chronic condition (e.g. psychiatric disorder, chronic obstructive pulmonary disease Grade II, chronic heart failure \> NYHA II) * Cerebrospinal fluid infection or signs of meningoencephalitis * Acute respiratory distress syndrome (ARDS), pulmonary edema * Preexisting coagulation disorder * Patients with current alcohol or drug abusus or dependence * Patients with a history of hypersensitivity against indocyanine green or sodium iodine * Patients with thyroid disease causing hyperthyroidism * Breast-feeding women * Patients committed to an institution based on official directive or court order

Locations (1)

Department of Neurosurgery, University Hospital Heidelberg

Heidelberg, Germany

Outcomes

Primary Outcomes

To assess the feasibility of the neuromonitoring system and accuracy of the measurement values

Feasibility: User acceptance rate in comparison to conventional probes for ICP-monitoring. The following parameters will be analysed: * Incidence of concerns of users in relation to the installation of the NeMo System * Incidence of concerns of users in relation to the function of the NeMo System Incidence of concerns of users in relation to the removal of the NeMo System * User-friendliness with a 3-graded scale (equal, better, worse) compared to conventional probes for ICP monitoring Accuracy of measurement values: Results from repeated measurements of mttICG, CBV, and CBF. Safety endpoints: -Adverse events profile (including adverse device effects): Incidence of complications (infections, brain tissue damage, hemorrhage) in comparison to historical series (conventional probes for ICP-monitoring):

Time frame: Day 90 after Removal of Medical Device

Secondary Outcomes

To demonstrate the ability of the neuromonitoring system to detect cerebrovascular events in patients with subarachnoid hemorrhage

Results concerning the response to cortical spreading depolarization (CSD) monitored with electrocorticography (ECoG): Increase of brain tissue oxygenation (SbtO2), total hemoglobin (dHbtotal, aHbtotal), CBV, CBV Hb and CBF \>20% Decrease of SbtO2, dHbtotal, aHbtotal, CBV, CBV Hb and CBF \>20% Changes of SbtO2, dHbtotal, aHbtotal, CBV, CBV Hb and CBF \<20% Results concerning the sensitivity and specificity to detect delayed cerebral ischemia (DCI) monitored with ptiO2 and MD: Correlation of CBF values \<15 ml/100g/min with defined criteria for DCI (ptiO2 \<15 mmHg, Gluc brain\<0.7 mmol/l, Lactate-Pyruvate-Ratio \>40), number of false negative and false positive events, Receiver Operating Characteristic (ROC) curve.

Time frame: Day 90 after Removal of Medical Device

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.